NCT04939844: Phase 2: REST - Replacing Steroids in the Transplant Ineligble (REST)

REST

NCT04939844: Phase 2: REST - Replacing Steroids in the Transplant Ineligble (REST)

Newly diagnosed multiple myeloma patients ineligible for HD-ASCT will be included in the study. All participants will receive isatuximab in combination with bortezomib, lenalidomide and minimal dexamethasone until disease progression. The primary objective of this study is the MRD negativity rate during and/or after first 18 cycles of study treatment.

Sponsor

Oslo University Hospital

Collaborators

Nordic Myeloma Study Group

St. Olavs Hospital

Helse Stavanger HF

Information provided by (Responsible Party)

Fredrik Hellem Schjesvold, Oslo University Hospital

Location